This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
May 12, 2026
•
3 min read
🧬 Inhibrx Biosciences' INBRX-106 plus Keytruda (pembrolizumab) doubles response rate in Ph2 head and neck squamous cell carcinoma trial, Daiichi Sankyo targets $14.6B oncology sales by 2030, aiming for global top-five cancer company status, Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy STEM-PD, equity investment undisclosed
May 11, 2026
🧬 Quantinuum plans IPO to fund quantum computing platform for drug discovery, Gilead raises Yeztugo 2026 sales target to $1B after strong launch trajectory, argenx's VYVGART (efgartigimod alfa-fcab) receives FDA label expansion for all adult generalized myasthenia gravis serotypes
May 8, 2026
🧬 Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1B, expanding into U.S. rare neurological drug market, Blackstone invests $250M in Anagram Therapeutics to develop cystic fibrosis EPI therapy, Pierre Fabre, FDA align on Ebvallo BLA resubmission path using updated ALLELE study data
May 7, 2026
🧬 Eli Lilly pledges additional $4.5B to Indiana campus, expanding genetic medicine and metabolic disease manufacturing, Bayer to acquire Perfuse Therapeutics for up to $2.45B, bolstering eye disease drug pipeline, Novo Nordisk's Wegovy pill hits 1M patients, generates $355M in Q1 sales, beating analyst expectations by 86%
May 6, 2026
🧬 Pfizer beats Q1 earnings with $14.5B revenue, maintains 2026 guidance despite COVID portfolio decline, Swiss private biotech funding surges 38% to record $1.5B in 2025, marking third straight year of growth, Sanofi invests $294M to expand Toronto AI center, targeting drug discovery and manufacturing acceleration
May 5, 2026
🧬 Amgen adds $300M to Puerto Rico biologics expansion, bringing total U.S. investment pledges near $2B, Windward Bio raises $165M crossover round, advancing TSLP-targeting immunology antibody programmes, Obesity surpasses oncology as top biopharma pipeline value contributor for first time, per Deloitte analysis
May 4, 2026
🧬 Arvinas' Veppanu (vepdegestrant) receives first-ever FDA approval for estrogen receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations, UCB to acquire Candid Therapeutics for $2.2B, expanding T-cell engager pipeline for autoimmune diseases, FDA names Katherine Szarama as acting CBER director following Vinay Prasad's departure
May 2, 2026
15 min read
Why securitization might be the way towards greater CGT and advanced therapy access
May 1, 2026
4 min read
🧬 Axsome Therapeutics' Auvelity (dextromethorphan/bupropion) receives FDA approval for agitation associated with Alzheimer's disease dementia, AstraZeneca licenses preclinical EGFR degrader from Pinetree Therapeutics for $25M, up to $500M milestones, UniQure to seek UK approval for Huntington's gene therapy AMT-130, shares surge 20%
Apr 30, 2026
🧬 GSK's Shingrix strategy shift targeting comorbid patients drives $1.4B Q1 sales, beating analyst forecasts, Chiesi acquires KalVista Pharmaceuticals for $1.9B, gaining rare disease oral HAE treatment Ekterly, Avalyn Pharma raises $300M IPO to develop drugs for hard-to-treat lung diseases
Apr 29, 2026
🧬 AbbVie gains exclusive right to acquire Kestrel Therapeutics for up to $1.45B - targeting oral pan-KRAS inhibitor, Coultreon Biopharma raises $125M Series A to advance oral SIK3 autoimmune drug, Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180M, Eli Lilly + Profluent Bio partner on AI-designed DNA editing tools for genetic medicines - up to $2.25B milestones
Apr 28, 2026
🧬 Rejuvenate Bio launches crowdfunding campaign to advance gene therapy for aging + chronic diseases, Intellia Therapeutics' lonvo-z succeeds in Ph3 trial for hereditary angioedema - company begins rolling FDA submission, Thermo Fisher Scientific divests microbiology business to Astorg for $1.075B, UK biotech VC funding rises 17% in Q1 2026 - showing recovery signs but IPO activity remains stagnant
